

## Abstract

The advent of oral antineoplastic medications has brought remarkable convenience to cancer treatment, allowing patients to manage their therapy at home. However, this convenience comes with the potential for delayed care, which can significantly impact treatment outcomes. This abstract provides a concise overview of the complexities surrounding the assessment of delay in care caused by oral antineoplastic medications.

Oral antineoplastic drugs represent a paradigm shift in cancer treatment, offering patients the autonomy to self-administer their medication outside the traditional clinical setting. While this approach enhances the quality of life for patients, it introduces a unique set of challenges. Delay in care can manifest through missed doses, inconsistent adherence, and a lack of adequate monitoring, potentially leading to disease progression, increased toxicity, and reduced survival rates.

## Introduction

The advent of oral antineoplastic medications has brought remarkable convenience to cancer treatment, allowing patients to manage their therapy at home. However, this convenience comes with the potential for delayed care, which can significantly impact treatment outcomes. This abstract provides a concise overview of the complexities surrounding the assessment of delay in care caused by oral antineoplastic medications.

Oral antineoplastic drugs represent a paradigm shift in cancer treatment, offering patients the autonomy to self-administer their medication outside the traditional clinical setting. While this approach enhances the quality of life for patients, it introduces a unique set of challenges. Delay in care can manifest through missed doses, inconsistent adherence, and a lack of adequate monitoring, potentially leading to disease progression, increased toxicity, and reduced survival rates.

## Understanding oral antineoplastic medications

The advent of oral antineoplastic medications has brought remarkable convenience to cancer treatment, allowing patients to manage their therapy at home. However, this convenience comes with the potential for delayed care, which can significantly impact treatment outcomes. This abstract provides a concise overview of the complexities surrounding the assessment of delay in care caused by oral antineoplastic medications.

### e convenience dilemma

Oral antineoplastic drugs represent a paradigm shift in cancer treatment, offering patients the autonomy to self-administer their medication outside the traditional clinical setting. While this approach enhances the quality of life for patients, it introduces a unique set of challenges. Delay in care can manifest through missed doses, inconsistent adherence, and a lack of adequate monitoring, potentially leading to disease progression, increased toxicity, and reduced survival rates.

### Assessing delay in care

The advent of oral antineoplastic medications has brought remarkable convenience to cancer treatment, allowing patients to manage their therapy at home. However, this convenience comes with the potential for delayed care, which can significantly impact treatment outcomes. This abstract provides a concise overview of the complexities surrounding the assessment of delay in care caused by oral antineoplastic medications.

**\*Corresponding author:** Cinzia Salmina, Department of Pathology, Peking University School of Stomatology, Beijing, China, E-mail: salminaciniza455@gmail.com

**Received:** 03-Oct-2023, Manuscript No: jdpm-23-118281, **Editor assigned:** 06-Oct-2023, Pre-QC No: jdpm-23-118281 (PQ), **Reviewed:** 20-Oct-2023, QC No: jdpm-23-118281, **Revised:** 26-Oct-2023, Manuscript No: jdpm-23-118281 (R) **Published:** 31-Oct-2023, DOI: 10.4172/jdpm.1000179

**Citation:** Salmina C (2023) Assessing Delay in Care Caused by Oral Antineoplastic Medications. J Dent Pathol Med 7: 179.

**Copyright:** © 2023 Salmina C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Missed doses:** [Illegible text]

**Inconsistent adherence:** [Illegible text]

**Inadequate monitoring:** [Illegible text]

### Impact on patient outcomes

[Illegible text]

### Addressing the challenge

**Patient education:** [Illegible text]

**Regular monitoring:** [Illegible text]

**Support systems:** [Illegible text]

**Individualized care plans:** [Illegible text]

### Conclusion

[Illegible text]

[Illegible text]

### References

1. Iyer P, Aziz K, Ojcius DM (2020) Impact of COVID-19 on Dental Education in the United States. J Dent Educ 84: 718-722.
2. Chang TY, Hong G, Paganelli C, Phantumvanit P, Chang WJ, et al. (2021) Innovation of Dental Education During COVID-19 Pandemic. J Dent Sci 16: